AM 831

Drug Profile

AM 831

Alternative Names: AM831; PCAP programme

Latest Information Update: 18 Jul 2012

Price : $50

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Muscarinic M1 receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 13 Jul 2012 Discontinued - Phase-I for Schizophrenia in USA (PO)
  • 09 Nov 2011 Phase-I clinical trials in Schizophrenia in USA (PO)
  • 07 Nov 2011 US FDA approves IND application for AM 831 in Schizophrenia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top